November 10th, 2010

Reports the Philadelphia Inquirer:

Endo Pharmaceuticals Holdings Inc. chief executive David P. Holveck was described Monday at a Pennsylvania Bio event as an “icon” for the life-sciences industry in this region.

As he began his keynote address, Holveck refrained from commenting on what his career might symbolize, but was grateful that he wasn’t being called a “model,” which his wife had told him means a “small replica of something larger and real.”

In fact, Holveck is the executive who turned around Centocor Inc. in the ’90s after the failure of its lead compound and later sold it to Johnson & Johnson. Now engaged in the recasting of Chadds Ford-based Endo through a series of acquisitions, he can say with the force of experience that “drug development remains an expensive entrepreneurial pursuit with uncertain results.”

Read More of the the article.